Form 4 for INSM INSMED Inc
Accepted 2025-07-09 00:00:00 ET · period of report 2025-07-07 · accession 0001604019-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-07-09 | 2025-07-07 | INSM | Bonstein Sara | CFO | S - Sale+OE | $95.86 | -57.8K | 106.2K | -35% | -$5.54M |
| DM | 2025-07-09 | 2025-07-07 | INSM | Bonstein Sara | CFO | M - OptEx | $25.41 | +47.9K | 141.8K | +51% | +$1.22M |
| DM | 2025-07-09 | 2025-07-07 | INSM | Bonstein Sara | CFO | M - OptEx | $0.00 | -47.9K | 18.9K | -72% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-07 | S | D | 22,181 | $96.19 | 84,017 | D | — | — | (F4) This is the weighted average sales price representing 22,181 shares sold at prices ranging from $96.01 to $96.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 2 | Common | Common Stock | 2025-07-07 | M | A | 4,362 | $24.70 | 104,499 | D | — | — | |
| 3 | Common | Common Stock | 2025-07-07 | M | A | 23,565 | $26.43 | 128,064 | D | — | — | |
| 4 | Common | Common Stock | 2025-07-07 | M | A | 6,244 | $19.74 | 100,137 | D | — | — | (F2) Includes 357 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
| 5 | Common | Common Stock | 2025-07-07 | S | D | 35,583 | $95.66 | 106,198 | D | — | — | (F3) This is the weighted average sales price representing 35,583 shares sold at prices ranging from $95.01 to $96.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 6 | Common | Common Stock | 2025-07-07 | M | A | 13,717 | $26.46 | 141,781 | D | — | — | |
| 7 | Derivative | Stock Option (right to buy) | 2025-07-07 | M | D | 13,717 | $0.00 | 12,023 | D | $26.46 · — to 2031-05-12 | 13,717 Common Stock | (F6) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |
| 8 | Derivative | Stock Option (right to buy) | 2025-07-07 | M | D | 23,565 | $0.00 | 15,710 | D | $26.43 · — to 2032-01-06 | 23,565 Common Stock | (F5) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 9 | Derivative | Stock Option (right to buy) | 2025-07-07 | M | D | 4,362 | $0.00 | 0 | D | $24.70 · — to 2030-05-12 | 4,362 Common Stock | (F6) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |
| 10 | Derivative | Stock Option (right to buy) | 2025-07-07 | M | D | 6,244 | $0.00 | 18,880 | D | $19.74 · — to 2033-01-05 | 6,244 Common Stock | (F5) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |